Adjuvant therapy for early uterine high-grade leiomyosarcoma

TO THE EDITOR: The article by Hensley et al1 recently published in Journal of Clinical Oncology was interesting, even if apparently negative (Gynecology Oncology Group [GOG]-0277 randomized phase III trial). The study investigated the activity and safety of gemcitabine plus docetaxel followed by doxorubicin versus observation in patients with uterus-limited, highgrade leiomyosarcoma (LMS) in an adjuvant setting. Although the study was closed for accrual futility, available survival results (disease-free survival, overall survival) failed to show better outcomes in the experimental arm. This is probably, for different reasons, the typical study that should not have been started or completed. Adjuvant therapy for early-stage uterine LMS remains controversial, and at the moment, cannot be recommended.